Medicenna Therapeutics
Market cap $14.8M 92.3M shares (vendor count, Nov 18, 2026) × $0.160 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page
Most recent annual filing: 2023-06-27
- MDNA11 interim2H 2026MDNA11 interim, 2H 2026, material
- MDNA11 FDA feedback2H 2026MDNA11 FDA feedback, 2H 2026, notable
- MDNA113 IND filing2027MDNA113 IND filing, 2027, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (10 active programs)
MDNA11
MDNA19
- Undisclosed indication
MDNA223
- Undisclosed indication
MDNA413
- Undisclosed indication
MDNA132
- Undisclosed indication
MDNA213
- Undisclosed indication
MDNA209
- Undisclosed indication
MDNA113
- Undisclosed indication
Technology platforms
BiSKITs
Bi-functional SuperKine ImmunoTherapies platform that fuses IL-2, IL-4, and/or IL-13 Superkines with proteins, antibodies, checkpoint inhibitors, or other Superkines to create dual-function molecules for treatment of cancers, including immunologically cold tumors
Targets: IL-2Rβ, PD-1, IL-4R, IL-13Rα2, IL-2
T-MASK
Targeted Metalloprotease Activated SuperKine platform — conditionally activates IL-2 Superkine payloads via tumor-associated MMP cleavage and proximity-dependent unmasking in the tumor microenvironment; focus on solid tumors
Targets: MMP, IL-13Rα2, PD-1, IL-2, CD122, IL-15
BiSKIT
Bifunctional Superkine immunotherapy platform used to develop targeted cytokine fusion candidates, including PD-1 x IL-2 bifunctional immunotherapies for solid tumors
Targets: PD-1, IL-2
Capital (as filed)
- Cash
- C$33.6M cash and cash equivalents · Mar 31, 2023 (20-F) · more than a year old
- Operating cash flow
- −C$12.7M quarter to Mar 31, 2023 (20-F)
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (12)
- 2026-11-18 UPDATE: Medicenna Therapeutics (MDNAF) - The Cash Line Arrives 🔒 Paid
- 2026-11-17 UPDATE: Medicenna Therapeutics (MDNAF) - Bizaxofusp Doubles Survival at SNO, on Borrowed Controls 🔒 Paid
- 2026-11-10 UPDATE: Medicenna Therapeutics (MDNAF) - The First Q4 Oral Lands: 40% at SITC, With an Asterisk 🔒 Paid
- 2026-10-02 UPDATE: Medicenna Therapeutics (MDNAF) - The Reverse Split Gets a Green Light
- 2026-08-15 UPDATE: Medicenna Therapeutics (MDNAF) - Two Oral Slots, One Slipped IND, and Sorbie Still in Forward-Looking Tense 🔒 Paid
- 2026-06-26 UPDATE: Medicenna Therapeutics (MDNAF) - FY2026 Results, a “Fractional” CMO, and the Sorbie Clock 🔒 Paid
- 2026-05-28 UPDATE: Medicenna Therapeutics (MDNAF) - The Marketed Tranche Closes at CDN$4.44M, Sorbie Still Pending 🔒 Paid
- 2026-05-22 UPDATE: Medicenna Therapeutics (MDNAF) - The Prospectus Supplement Drops, and a Sorbie Wrinkle Appears 🔒 Paid
- 2026-05-19 UPDATE: Medicenna Therapeutics (MDNAF) - The Pricing Print Lands, and the Tape Tells You Everything 🔒 Paid
- 2026-05-14 UPDATE: Medicenna Therapeutics (MDNAF) - The Dilution Headline Lands 🔒 Paid
- 2026-04-27 UPDATE: Medicenna Therapeutics (MDNAF) - The Science Wins, the Cash Cliff Looms Closer 🔒 Paid
- 2026-03-20 Medicenna Therapeutics (MDNAF) - Scientific Deep Dive for MDNA11 and Pipeline Products
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (12 calls)
Every verdict Biotech Distilled has published on Medicenna Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-03-20 Watch Medicenna Therapeutics (MDNAF) - Scientific Deep Dive for MDNA11 and Pipeline Products Elegant protein engineering and real clinical responses, but dire balance sheet and Q3 2026 cash cliff make buying premature until dilution risk is cleared via a bizaxofusp partnership or capital raise.
- 2026-04-27 Watch UPDATE: Medicenna Therapeutics (MDNAF) - The Science Wins, the Cash Cliff Looms Closer MDNA113 AACR data validated the architecture thesis and CMO hire adds M&A credibility, but no partnership materialized and the cash clock is now one quarter away, keeping the setup binary and watch-only.
- 2026-05-14 Avoid UPDATE: Medicenna Therapeutics (MDNAF) - The Dilution Headline Lands The bear-case dilutive raise has arrived with no accompanying partnership; stepping in front of a marketed offering before the price prints is bad math given float expansion and likely warrant overhang.
- 2026-05-19 Watch UPDATE: Medicenna Therapeutics (MDNAF) - The Pricing Print Lands, and the Tape Tells You Everything Offering terms are now in the tape with confirmed warrant overhang, but the Prospectus Supplement with actual price, size, and warrant terms must be read before sizing any position.
- 2026-05-22 Speculative buy speculative UPDATE: Medicenna Therapeutics (MDNAF) - The Prospectus Supplement Drops, and a Sorbie Wrinkle Appears The Sorbie Bornholm 16M-unit anchor plus a non-dilutive Sharing Agreement kicker makes the structure more creative than a standard discounted raise, partially satisfying the non-dilutive bridge condition that was the original buy trigger.
- 2026-05-28 Speculative buy speculative UPDATE: Medicenna Therapeutics (MDNAF) - The Marketed Tranche Closes at CDN$4.44M, Sorbie Still Pending Marketed tranche cleared the binary tripwire but came in at the floor of the range; Sorbie close remains the swing factor between a real multi-quarter bridge and a months-long partial one.
- 2026-06-26 Speculative buy speculative UPDATE: Medicenna Therapeutics (MDNAF) - FY2026 Results, a "Fractional" CMO, and the Sorbie Clock Science thesis reaffirmed with Q4 2026 catalyst calendar now sharper, but Sorbie still unconfirmed five weeks on and the CMO disclosed as fractional dilutes the Merck-deal tea-leaf read.
- 2026-08-15 Speculative buy speculative UPDATE: Medicenna Therapeutics (MDNAF) - Two Oral Slots, One Slipped IND, and Sorbie Still in Forward-Looking Tense Two oral presentation slots for lead assets at Q4 conferences sharpen the partner-facing catalyst stack, but MDNA113 IND slipped to 2027, Sorbie remains unconfirmed twelve weeks on, and the financing window and data window are uncomfortably close.
- 2026-10-02 Hold UPDATE: Medicenna Therapeutics (MDNAF) - The Reverse Split Gets a Green Light Reverse-split authorization signals a likely U.S. listing and raise is coming; downgraded from Speculative Buy as the risk of another raise before the Q4 data stack has moved from abstract to visible, but not yet AVOID since no ratio or offering has been announced.
- 2026-11-10 Hold UPDATE: Medicenna Therapeutics (MDNAF) - The First Q4 Oral Lands: 40% at SITC, With an Asterisk MDNA11 posts a credible 31% ICI-refractory GI response rate at SITC with a named registrational indication, but confirmed ORR is 25%, Sorbie remains unconfirmed, and two of three Q4 events still pending.
- 2026-11-17 Hold UPDATE: Medicenna Therapeutics (MDNAF) - Bizaxofusp Doubles Survival at SNO, on Borrowed Controls Bizaxofusp delivers strongest-ever clinical package with FDA-endorsed Phase 3 design at SNO, but financing remains unresolved with Sorbie unconfirmed, conditional runway nearly expired, and a 17.5% weekly slide into two positive orals signals the market is pricing the cap table.
- 2026-11-18 Avoid UPDATE: Medicenna Therapeutics (MDNAF) - The Cash Line Arrives $3.7M cash with an explicit twelve-month going-concern warning, vanished Sorbie mention, lost runway guidance, and undated NEO-CYT readout signal a forced raise is imminent at distressed pricing before remaining catalysts can land.
- Avoid call · opened May 14, 2026 at $0.404 · closed May 20, 2026 (downgraded to WATCH from avoid) at $0.323 · -20.0% vs XBI -2.4%
- Long call · opened May 26, 2026 at $0.322 · closed Nov 18, 2026 (flipped bearish (avoid)) at $0.160 · -50.3% vs XBI +9.1%
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (20)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Apr 30, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 17, 2026ReleaseMedicenna Therapeutics Reports Second Quarter Fiscal 2027 Financial Results and Provides Corporate Update→ BD updateABILITY-1 closes at 152 patients with response rates intact, but the Q2 financials reveal only $3.7M CAD in the bank, Sorbie still unconfirmed, and a stock -37% — the cash cliff has arrived in real time.
- Nov 16, 2026ReleaseMedicenna Reports More than Doubling of Median Overall Survival in Glioblastoma Patients With Unresectable Recurrent IDH-WT Tumors Following One Treatment with Bizaxofusp Versus a Matched External Con→ BD updateThe second of Medicenna's Q4 data events landed today at SNO 2026: bizaxofusp more than doubled median overall survival versus a matched external control in the Phase 3-relevant IDH-WT glioblastoma population — the strongest partnership-predicate package the company has ever assembled, arriving while the stock is down 17.5% on the week and the Sorbie clock is still ticking.
- Nov 9, 2026ReleaseMedicenna Presents ABILITY-1 Data at SITC 2026 Showing 40% ORR in Gastrointestinal Cancer Patients with Biomarker Enriched Tumors Resistant to Approved Therapies→ BD updateThe SITC 2026 oral slot delivered: 40% ORR and 80% disease control in checkpoint-refractory GI cancers with durability data not yet reached — the strongest MDNA11 readout to date, arriving exactly when the thesis said it needed to.
- Nov 4, 2026ReleaseMedicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion Leaders
- Oct 26, 2026ReleaseMedicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease
- Oct 22, 2026ReleaseMedicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference
- Oct 5, 2026ReleaseMedicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026BD extracted 1 program update from this document → MDNAF pipeline
- Oct 1, 2026ReleaseMedicenna Announces Results of Annual General and Special Meeting of Shareholders
- Sep 24, 2026ReleaseMedicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting
- Sep 3, 2026ReleaseMedicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Aug 14, 2026ReleaseMedicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming ConferencesBD extracted 1 program update from this document → MDNAF pipeline
- Jun 26, 2026ReleaseMedicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational HighlightsBD extracted 2 program updates from this document → MDNAF pipeline
- Jun 11, 2026ReleaseMedicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
- Jun 3, 2026ReleaseMedicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
- May 28, 2026ReleaseMedicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs
- May 22, 2026ReleaseMedicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
- May 19, 2026ReleaseMedicenna Announces the Finalization of the Terms of its Public Offering of Securities
- May 13, 2026ReleaseMedicenna Announces the Launch of a Marketed Public Offering of Securities
- May 12, 2026ReleaseMedicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
- Apr 30, 2026ReleaseMedicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
1 more filing (13G holder notices, S-8, proxy material, SEC correspondence …)
- Jul 6, 2026DForm D (exempt offering)